Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo

Rhonda Bentley-Lewis, David Aguilar, Matthew C Riddle, Brian Claggett, Rafael Diaz, Kenneth Dickstein, Hertzel C Gerstein, Peter Johnston, Lars V Køber, Francesca Lawson, Eldrin F Lewis, Aldo P Maggioni, John J V McMurray, Lin Ping, Jeffrey L Probstfield, Scott D Solomon, Jean-Claude Tardif, Yujun Wu, Marc A Pfeffer, ELIXA Investigators (Henrik Nielsen, members)Jørgen Rungby (Medlem af forfattergruppering)

88 Citationer (Scopus)

Abstract

BACKGROUND: Cardiovascular (CV) disease is the leading cause of morbidity and mortality in patients with type 2 diabetes mellitus (T2DM). Furthermore, patients with T2DM and acute coronary syndrome (ACS) have a particularly high risk of CV events. The glucagon-like peptide 1 receptor agonist, lixisenatide, improves glycemia, but its effects on CV events have not been thoroughly evaluated.

METHODS: ELIXA (www.clinicaltrials.gov no. NCT01147250) is a randomized, double-blind, placebo-controlled, parallel-group, multicenter study of lixisenatide in patients with T2DM and a recent ACS event. The primary aim is to evaluate the effects of lixisenatide on CV morbidity and mortality in a population at high CV risk. The primary efficacy end point is a composite of time to CV death, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for unstable angina. Data are systematically collected for safety outcomes, including hypoglycemia, pancreatitis, and malignancy.

RESULTS: Enrollment began in July 2010 and ended in August 2013; 6,068 patients from 49 countries were randomized. Of these, 69% are men and 75% are white; at baseline, the mean ± SD age was 60.3 ± 9.7 years, body mass index was 30.2 ± 5.7 kg/m(2), and duration of T2DM was 9.3 ± 8.2 years. The qualifying ACS was a myocardial infarction in 83% and unstable angina in 17%. The study will continue until the positive adjudication of the protocol-specified number of primary CV events.

CONCLUSION: ELIXA will be the first trial to report the safety and efficacy of a glucagon-like peptide 1 receptor agonist in people with T2DM and high CV event risk.

OriginalsprogEngelsk
TidsskriftAmerican Heart Journal
Vol/bind169
Udgave nummer5
Sider (fra-til)631-638.e7
ISSN0002-8703
DOI
StatusUdgivet - maj 2015

Fingeraftryk

Dyk ned i forskningsemnerne om 'Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo'. Sammen danner de et unikt fingeraftryk.

Citationsformater